FDA grants Breakthrough Device Designation to Glucommander Pediatrics for IV insulin dosing

Glytec announced that the FDA has granted Breakthrough Device Designation to Glucommander Pediatrics, a proposed insulin-dosing recommendation algorithm for hospitalized patients from birth to younger than 2 years who require continuous intravenous (IV) insulin. The designation does not clear the product for clinical use.¹

For neonatal and pediatric intensive care teams, the proposed tool addresses a difficult dosing task: adjusting IV insulin in small, acutely ill patients whose glucose concentrations may change rapidly. “Care for newborns and infants’ sits at the far end of that problem, where the physiology is least stable, and the available tools are fewest,” Patrick Cua, Glytec’s CEO, said in the announcement.¹

Designation, not clearance

Glytec described Glucommander Pediatrics as a separate, prescription-only product intended for hospitalized neonates and infants receiving continuous IV insulin for life-threatening or irreversibly debilitating conditions. The company listed diabetic ketoacidosis, hyperglycemic hyperosmolar state, hyperglycemia of prematurity, and persistent hyperglycemia during intensive care among the potential clinical settings. The designation covers patients from birth to younger than 2 years; it does not extend an existing clearance to that age group.¹

The FDA’s Breakthrough Devices Program is intended to facilitate development and review of devices for serious conditions when program criteria are met. Breakthrough designation is a regulatory milestone, but it is not a determination that a device is safe or effective for its proposed use. Clinicians should therefore distinguish the announced designation from authorization to deploy the pediatric algorithm in a neonatal intensive care unit (NICU) or pediatric intensive care unit (PICU).

The announcement did not identify a pediatric trial, describe a study population, or report prespecified efficacy or safety endpoints for Glucommander Pediatrics. It provided no comparative results for time in a target glucose range, hypoglycemia, dosing errors, or patient outcomes. Whether the proposed recommendations improve care over locally used IV insulin protocols remains unanswered.¹

Clinical context and existing technology

Glytec stated that hyperglycemia is common in critically ill newborns and premature infants and is associated with poor outcomes. In patients who require an IV insulin infusion, frequent glucose measurement and repeated dose adjustments create substantial demands on clinical teams. Hypoglycemia and dosing mistakes are particularly important safety concerns when insulin is given to patients with low body weight. However, the designation announcement does not specify appropriate glucose targets or adjustment schedules.¹

The company’s existing Glucommander platform has been FDA-cleared since 2006, according to Glytec. It said subsequent clearances have included IV and subcutaneous insulin-dosing functions and use in patients aged 2 to 17 years beginning in 2012. Those prior clearances do not establish the performance of the proposed product in children younger than 2 years. Glytec also asserted that technology-supported titration has improved adult intensive care glucose control compared with paper protocols, but it supplied no study results that would support applying that finding to infants.¹

The proposed pediatric product would use an algorithm to generate insulin-dosing recommendations rather than replace bedside assessment. Before adoption could be considered, clinicians would need evidence describing how its recommendations perform across the intended age range and clinical conditions, including in premature infants.

Reference

1. Glytec, LLC. Glytec receives FDA Breakthrough Device Designation for Glucommander Pediatrics, an insulin management technology for hospitalized newborns and infants. PR Newswire. Published September 24, 2026. https://www.prnewswire.com/news-releases/glytec-receives-fda-breakthrough-device-designation-for-glucommander-pediatrics-an-insulin-management-technology-for-hospitalized-newborns-and-infants-302889288.html